GlaxoSmithKline headquaters. (Credit: Maxwell Hamilton via Wikimedia Commons)
GlaxoSmithKline told a Delaware federal judge on Monday that it will seek enhanced damages on a $235 million verdict against Teva Pharmaceutical for willfully infringing a patent for its hypertension drug Coreg.
*May exclude premium content
Already have an account? Sign In Now
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to email@example.com to learn more.